- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04004078
An Individualized Administration Research of Voriconazole Based on CYP2C19 Gene Polymorphism and TDM
An Individualized Administration Research of Voriconazole Based on CYP2C19 Gene Polymorphism and Therapeutic Drug Monitoring in Chinese Patients With Invasive Pulmonary Infection
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This was a prospective clinical study that all voriconazole-treated adult Chinese patients with invasive pulmonary infection admitted to Zhengzhou Central Hospital affiliated to Zhengzhou University from March 2018 to April 2020. Patients were included who met the following criteria:(1)age≥18 years old, (2)Diagnosis of invasive fungal infection,(3)written informed consent was obtained from each patients,(4)At least one steady trough concentration blood sample was taken from each patient.
Patients were excluded who fulfilled any of the following criteria:(1) patients who are allergic to voriconazole or have poor compliance, (2) use other antifungal drugs during the use of VCZ, (3) do not qualify for blood sampling monitored by blood concentration, (4) patients with severe liver function impairment (ALT and AST before VCZ treatment are greater than 5 times the normal upper limit, TBIL is greater than 3 times the normal upper limit), 5) pregnant or lactating women, (6) with incomplete clinical data collection, (7) have participated in other clinical trials in the past three months.
Grouping: 1) The patients were grouped according to CYP2C19 gene detection, they were divided into gene-directed group and non-gene-directed group; 2) According to the effect of treatment, the patients were divided into effective group and ineffective group; 3) According to whether patients had adverse reactions, they were divided into group A (adverse reactions) and group B (no adverse reactions). The clinical indicators and detection values of each group were recorded, respectively.
Loading Dosage of administration and treatment regimen : All the selected patients were treated with VCZ. Dose of administration is shown for gene-directed group and non-gene-directed group below. The maintenance dosage was increased or decreased appropriately up to target Cmin range (0.5μg/ml~5.0μg/ml).
According to CYP2C19 gene detection, phenotypes were classified as ultrarapid metabolisers(UMs),extensive metabolisers(EMs) ,intermediate metabolisers(IMs) and poor metabolisers(PMs).
Dose of administration and treatment regimen according to CYP2C19 gene detection:(1)Non- gene directed group:Voriconazole was intravenously administered 2 times at the loading dose of 6mg/Kg at 12h intervals , followed by maintenance dosing 4mg/Kg at 12h intervals . Voriconazole was oral administered 2 times at the loading dose of 400mg or 200mg(weight>40Kg or <40Kg)at 12h intervals , followed by maintenance dosing 200mg or 100mg(weight>40Kg or <40Kg). Voriconazole was sequential therapy administered 2 times at the loading dose of 6mg/Kg at 12h intervals , followed by maintenance dosing 200mg or 100mg(weight>40Kg or <40Kg). (2) Gene directed group: The dosage of the drug was the same as that of the non-gene-directed group for patients with UMs,EMs and IMs. For the patients with PMs,Voriconazole was intravenously administered 2 times at the loading dose of 4mg/Kg at 12h intervals , followed by maintenance dosing 3mg/Kg at 12h intervals . Voriconazole was oral administered 2 times at the loading dose of 200mg or 100mg(weight>40Kg or <40Kg) at 12h intervals , followed by maintenance dosing 100mg . Voriconazole was sequential therapy administered 2 times at the loading dose of 4mg/Kg at 12h intervals , followed by maintenance dosing 100mg.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Henan
-
Zhengzhou, Henan, China, 41
- Zhengzhou Central Hospital affiliated to Zhengzhou University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- age≥18 years old
- Diagnosis of invasive fungal infection
- written informed consent was obtained from each patients
- At least one steady trough concentration blood sample was taken from each patient
Exclusion Criteria:
- patients who are allergic to voriconazole or have poor compliance
- use other antifungal drugs during the use of VCZ
- do not qualify for blood sampling monitored by blood concentration
- patients with severe liver function impairment (ALT and AST before VCZ treatment are greater than 5 times the normal upper limit, TBIL is greater than 3 times the normal upper limit)
- pregnant or lactating women,
- with incomplete clinical data collection
- have participated in other clinical trials in the past three months
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Group A
Non-gene directed group:Voriconazole was intravenously administered 2 times at the loading dose of 6mg/Kg at 12h intervals , followed by maintenance dosing 4mg/Kg at 12h intervals .
Voriconazole was oral administered 2 times at the loading dose of 400mg or 200mg(weight>40Kg or <40Kg)at 12h intervals , followed by maintenance dosing 200mg or 100mg(weight>40Kg or <40Kg).
Voriconazole was sequential therapy administered 2 times at the loading dose of 6mg/Kg at 12h intervals , followed by maintenance dosing 200mg or 100mg(weight>40Kg or <40Kg).
|
If treatment failure for patients in group A,group B,group C and group D,change other antifungal agents(Amphotericin B for Injection,25mg,North China Pharmaceutical Co., Ltd or Caspofungin Acetate for lnjection,50mg and 70mg Cancidas®).
Mechanical ventilation((EVITA 4, Dräger Medical Equipment (Shanghai) Co.,Ltd) was adopte.Treatment failure was defined as no improvement or worse of clinical symptoms, laboratory data, requiring change of antifungal agents therapy.
|
Group B
Gene directed group(UMs and EMs):The dosage of the drug was the same as that of the non-gene-directed group for patients with UMs,EMs.
|
If treatment failure for patients in group A,group B,group C and group D,change other antifungal agents(Amphotericin B for Injection,25mg,North China Pharmaceutical Co., Ltd or Caspofungin Acetate for lnjection,50mg and 70mg Cancidas®).
Mechanical ventilation((EVITA 4, Dräger Medical Equipment (Shanghai) Co.,Ltd) was adopte.Treatment failure was defined as no improvement or worse of clinical symptoms, laboratory data, requiring change of antifungal agents therapy.
|
Group C
Gene directed group(IMs):The dosage of the drug was the same as that of the non-gene-directed group for patients with IMs.
|
If treatment failure for patients in group A,group B,group C and group D,change other antifungal agents(Amphotericin B for Injection,25mg,North China Pharmaceutical Co., Ltd or Caspofungin Acetate for lnjection,50mg and 70mg Cancidas®).
Mechanical ventilation((EVITA 4, Dräger Medical Equipment (Shanghai) Co.,Ltd) was adopte.Treatment failure was defined as no improvement or worse of clinical symptoms, laboratory data, requiring change of antifungal agents therapy.
|
Group D
Gene directed group(PMs): Voriconazole was intravenously administered 2 times at the loading dose of 4mg/Kg at 12h intervals , followed by maintenance dosing 3mg/Kg at 12h intervals .
Voriconazole was oral administered 2 times at the loading dose of 200mg or 100mg(weight>40Kg or <40Kg)at 12h intervals , followed by maintenance dosing 100mg .
Voriconazole was sequential therapy administered 2 times at the loading dose of 4mg/Kg at 12h intervals , followed by maintenance dosing 100mg.
|
If treatment failure for patients in group A,group B,group C and group D,change other antifungal agents(Amphotericin B for Injection,25mg,North China Pharmaceutical Co., Ltd or Caspofungin Acetate for lnjection,50mg and 70mg Cancidas®).
Mechanical ventilation((EVITA 4, Dräger Medical Equipment (Shanghai) Co.,Ltd) was adopte.Treatment failure was defined as no improvement or worse of clinical symptoms, laboratory data, requiring change of antifungal agents therapy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum voriconazole trough concentrations
Time Frame: 0.5 hour before voriconazole administration on the Thirdth or sixth day
|
If all patients were administrated by loading dose, voriconazole trough samples were taken immediately 30 minutes before Voriconazole administration on the Third day.
If all patients were not administrated by loading dose, voriconazole trough samples were taken immediately 30 minutes before Voriconazole administration on the sixth day.
Blood samples for 2-3 mL were collected in blood-collection tubes without any additives and centrifuged at 3500 rpm for 10min.
Serum trough concentrations (Cmin) were determined by a high-performance liquid chromatography method as previously described.
The detections were completed in Translational Medicine Center of Zhengzhou Central Hospital affiliated to Zhengzhou University.
|
0.5 hour before voriconazole administration on the Thirdth or sixth day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The difference of average Cmin among group A, group B, group C and group D
Time Frame: From March 2018 to April 2020
|
The differences were counted among group A, group B, group C and group D by measuring each person's Cmin.
|
From March 2018 to April 2020
|
The correlation between Cmin and CRP, IL-6 and PCT
Time Frame: From March 2018 to April 2020
|
The correlation between Cmin and CRP, IL-6 and PCT by Pear's correlation analysis .CRP,IL-6 and PCT were completed before initiation ,after voriconazole therapy on day 3,7 and completion of voriconazole therapy in Zhengzhou city clinical inspection center.
|
From March 2018 to April 2020
|
The effect of voriconazole on liver injury biomarkers
Time Frame: From March 2018 to April 2020
|
The effects of different level of voriconazole-Cmin (<0.5,0.5-5,and>5μg/ml ) on liver injury biomarkers( ALT,AST,ALP and GGT ).The differences among 3groups were compared using one-way analysis of variance /post(Scheffe) test.They were determined before initiation ,after voriconazole therapy on day 3,7 and completion of voriconazole therapy in Zhengzhou city clinical inspection center.
|
From March 2018 to April 2020
|
Determination of Predictors of voriconazole Cmin
Time Frame: From March 2018 to April 2020
|
The voriconazole Cmin variation may be influenced by many factors.
A backward multiple linear regression model was performed for determination of predictors of voriconazole Cmin.
|
From March 2018 to April 2020
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Bacterial Infections and Mycoses
- Infections
- Mycoses
- Invasive Fungal Infections
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents, Local
- Anti-Infective Agents
- Enzyme Inhibitors
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Hormone Antagonists
- Steroid Synthesis Inhibitors
- 14-alpha Demethylase Inhibitors
- Cytochrome P-450 CYP2C9 Inhibitors
- Antifungal Agents
- Clotrimazole
- Miconazole
Other Study ID Numbers
- zhou750423
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Invasive Fungal Infection
-
Radboud University Medical CenterCompletedInvasive Fungal InfectionNetherlands
-
Melbourne HealthMerck Sharp & Dohme LLCRecruitingFungal Infection | Pharmacokinetics | Invasive Aspergillosis | Prophylaxis | Invasive Candidiases | Posaconazole | Invasive MycosisAustralia
-
People's Hospital of Zhengzhou UniversityRecruitingFactors on Therapeutic Drug Monitoring and Safety of Voriconazole in Critically Ill Elderly PatientsInvasive Fungal InfectionChina
-
Nantes University HospitalCompletedInvasive Fungal InfectionFrance
-
Astellas Pharma Global Development, Inc.CompletedInvasive Fungal InfectionUnited States
-
Asan Medical CenterWithdrawnInvasive Fungal InfectionKorea, Republic of
-
Merck Sharp & Dohme LLCRecruitingInvasive Fungal InfectionIsrael, United States, Belgium, Greece, Peru, Poland, Mexico, Russian Federation
-
Mayo ClinicRecruitingCandidiasis | Fungal InfectionUnited States
-
Merck Sharp & Dohme LLCCompleted
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityUnknown
Clinical Trials on other antifungal agents,breathing machine
-
People's Hospital of Zhengzhou UniversityCompletedPneumonia Gram-Positive Bacterial
-
University of California, San DiegoActive, not recruitingCritical Illness | Respiratory Failure | Renal Failure | Acute Respiratory Distress Syndrome | Pulmonary Disease | Extracorporeal Membrane Oxygenation Complication | Cardiac FailureUnited States
-
Azienda Ospedaliero, Universitaria PisanaFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico; Fondazione C.N.R...RecruitingEnd Stage Liver DIseaseItaly
-
People's Hospital of Zhengzhou UniversityRecruitingFactors on Therapeutic Drug Monitoring and Safety of Voriconazole in Critically Ill Elderly PatientsInvasive Fungal InfectionChina
-
Riphah International UniversityNot yet recruitingChronic Obstructive Pulmonary Disease
-
University of JordanRecruitingNon-specific Chronic Neck Pain | Diaphragmatic Breathing ExerciseJordan
-
Saglik Bilimleri UniversitesiNot yet recruitingTelerehabilitation | Breathing ExercisesTurkey
-
Drugs for Neglected DiseasesActive, not recruitingCutaneous LeishmaniasesPeru, Bolivia, Brazil, Panama
-
Balgrist University HospitalRecruiting
-
Zhang TianyuNot yet recruitingKidney TransplantationChina